This trial, brief called DOVACC, was initiated by the NSGO CTU and our former medical director Mansour Mirza. And in the trial, we tried to evaluate if the addition of the UV1 vaccine to a maintenance treatment of Olaparib and Durvalumab could increase the progression-free survival for patients with recurrent ovarian cancer. The patients have to have had platinum-based treatment and no more than three further lines...
This trial, brief called DOVACC, was initiated by the NSGO CTU and our former medical director Mansour Mirza. And in the trial, we tried to evaluate if the addition of the UV1 vaccine to a maintenance treatment of Olaparib and Durvalumab could increase the progression-free survival for patients with recurrent ovarian cancer. The patients have to have had platinum-based treatment and no more than three further lines. And the best results of the last line had to be stable disease or non-progressive disease. Then we randomized the patient one to one to two, one group receiving Olaparib, that was Arm A, Arm B receiving Olaparib and Durvalumab, and Arm C receiving Olaparib, Durvalumab, and then the experimental vaccine. And they had eight vaccines within the first few months of the trial. We saw the results of the study with their survival benefit towards the group who had the vaccine of 8.7 months compared to the Arm-A, which was our primary endpoint, the progression-free survival, Arm-C versus Arm-A. And the PFS in Arm-A was 5.9 months. Unfortunately, these results did not reach statistical significance. So we cannot say that adding the vaccine was proven to be a longer PFS, but it definitely showed that some patients do benefit from it. If we do look into the subgroups, we see that especially the subgroup of HRD patients and the subgroup of patients who had had no prior PARP could gain from adding the vaccine to a maintenance therapy. When we looked at our secondary endpoint, comparing Arm C to Arm B, comparing adding the vaccine to a combination of Durvalumab and Olaparib, unfortunately, we didn’t see any results that were statistically significant. So these are the prime efficacy endpoints. When we come to toxicity, really adding the vaccine to Olaparib and Durvalumab only added a few vaccine-related side effects like headache, flu, and some itching and redness where they had the vaccine. But of course adding Durvalumab to Olaparib added some more toxicity to the patients. But everything was manageable and we saw no grade 5 events. Generally the combination was well tolerated.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.